Ylenia Perone

Cholangioblastic variant of intrahepatic cholangiocarcinoma: a diagnostic challenge

Ylenia Perone, Lucia Lazzereschi, Tu Vinh Luong

gb (code pays fourni par la source)

Late cardiotoxicity related to HER2-targeted cancer therapy

Isabelle Senechal, María Sol Andrés, Jieli Tong, Ylenia Perone et autres

Long-term anti-HER2 therapy in metastatic HER2 + cancers is increasing, but data about the incidence and risk factors for developing late Cancer therapy-related cardiac dysfunction (CTRCD) are missing. We conducted a single-centre, retrospective analysis of a cohort of late anti-HER2 related cardiac …

gb, ca (code pays fourni par la source)

Impact of COVID-19 on 1-Year Survival Outcomes in Hepatocellular Carcinoma: A Multicenter Cohort Study

Shuell De Souza, Jeffrey Kahol de Jong, Ylenia Perone, Shishir Shetty et autres

INTRODUCTION: The COVID-19 pandemic has caused severe disruption of healthcare services worldwide and interrupted patients' access to essential services. During the first lockdown, many healthcare services were shut to all but emergencies. In this study, we aimed to determine the immediate and …

gb, de (code pays fourni par la source)

Impact of COVID19 on clinical outcomes in hepatocellular carcinoma:A multicentre cohort study

Shuell De Souza, Jeffery Kahol de Long, Ylenia Perone, Shishir Shetty et autres

Abstract Introduction: The COVID-19 pandemic has caused severe disruption of healthcare services worldwide and interrupted patients’ access to essential services. During the first lockdown, many healthcare services were shut to all but emergencies. In this study, we aimed to determine the immediate …

gb, de (code pays fourni par la source)

The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma

Claudia Angela Maria Fulgenzi, Ambreen Muhammed, Sirish Dharmapuri, Matthias Pinter et autres

fr, gb, us, at, Maroc, de, it, be, jp (code pays fourni par la source)

The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma

Ambreen Muhammed, Claudia Angela Maria Fulgenzi, Sirish Dharmapuri, Matthias Pinter et autres

Systemic inflammation is a hallmark of cancer, and it has a pivotal role in hepatocellular carcinoma (HCC) development and progression. We conducted a retrospective study including 362 patients receiving immune check-point inhibitors (ICIs) across three continents, evaluating the influence of neutrophiles to …

gb, it, us, at, tw, de, jp (code pays fourni par la source)

COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

Laia Garrigós, Cristina Saura, Clara Martínez-Vila, Alberto Zambelli et autres

Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients. Methods: We report a subanalysis of the OnCovid …

es, it, gb, fr, de, be (code pays fourni par la source)

Abstract P4-07-06: Breast cancer subtype classification using NanoString and RNAseq technologies

Andrea Rocca, Sara Ravaioli, Eugenio Fonzi, Iros Barozzi et autres

Abstract Background: Immunohistochemistry (IHC) is conventionally used in clinical practice to define Breast Cancer (BC) subtypes, while PAM50 is useful in specific cases. The former is partly subjective and semi-quantitative, the latter is based on gene expression profile. We compared gene expression …

it, gb (code pays fourni par la source)

Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention

Lisa M. Butler, Ylenia Perone, Jonas Dehairs, Leslie E. Lupien et autres

With the advent of effective tools to study lipids, including mass spectrometry-based lipidomics, lipids are emerging as central players in cancer biology. Lipids function as essential building blocks for membranes, serve as fuel to drive energy-demanding processes and play a key role …

au, gb, be, us (code pays fourni par la source)

Author Correction: SREBP1 drives keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer

Ylenia Perone, Aaron J. Farrugia, Alba Rodríguez-Meira, Balázs Győrffy et autres

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

gb, hu, it, es (code pays fourni par la source)

SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer

Ylenia Perone, Aaron J. Farrugia, Alba Rodríguez-Meira, Balázs Győrffy et autres

Approximately 30% of ERα breast cancer patients relapse with metastatic disease following adjuvant endocrine therapies. The connection between acquisition of drug resistance and invasive potential is poorly understood. In this study, we demonstrate that the type II keratin topological associating domain undergoes …

gb, hu, it, es (code pays fourni par la source)

OR34-2 SREBP1 Drives KRT80-Dependent Cytoskeletal Changes and Invasive Behaviour in Endocrine-Resistant ERα Breast Cancer

Ylenia Perone, Alba Rodríguez-Meira, A. Farruggia, Balázs Győrffy et autres

About one third of oestrogen receptor alpha breast cancer (ERα BC) patients progress to invasive metastatic disease despite targeted endocrine therapies(1). Our previous study showed how breast cancer cells developing resistance to aromatase inhibitors (AI) endogenously trigger cholesterol biosynthesis potentially through activation …

gb, hu, it (code pays fourni par la source)